Provider review
LumiMeds Review: The Cited Copy Is Gone, and the Term Is Non-Cancelable
FDA wrote to LumiMeds in 2025 about copy that gave a drug class an approval date and told readers its compounded products shared an active ingredient with the brand names. The sentences it quoted are gone, and the site now states that compounded medications are not FDA-approved. That correction is worth recording as precisely as the letter is.
Cited for calling compounded GLP-1s FDA-approved, and now says the opposite without being asked — with an open letter and an unnamed pharmacy still outstanding.
Worth trusting if
- You want a company whose disclaimer states plainly that compounded drugs are not FDA-approved
- You want NAD+ priced openly with no efficacy pitch attached
- You want a low entry figure and will get the rung, the length and the total in writing before paying
Be skeptical if
- You want the compounding pharmacy named
- You want the price of the plan you are actually buying — four lengths are offered and none of them is priced
- An open FDA warning letter would stop you buying, even one whose copy has been corrected
- You need to be able to stop — the membership terms say plans are non-cancelable and non-refundable once the term has commenced
Compounded only
Phase 3 trials
Not named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens www.lumimeds.com. A link is not a recommendation to take anything.
Provenance
What LumiMeds actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded GLP-1 injection — Read 2026-08-10 as an "as low as" figure with no term published. Re-read 2026-08-26: the term structure is now stated and the prices for it still are not. The product page says "MONTHLY, 3, 6, AND 12 MONTH OPTIONS AVAILABLE" above "as low as $89/mo", so the advertised figure is the floor of a four-rung ladder whose other three rungs are not published anywhere. Compounded tirzepatide is a separate product at $125/mo on the same basis. The "Pricing" link in the site's own navigation leads to a page that does not exist. Before you pay, read the membership terms: "Membership plans are non-cancelable and non-refundable" and "All outstanding payments for the remainder of the commitment term shall remain due and payable."
- NAD+ injectable — $119/mo as a floor, on the same monthly, three-, six- and twelve-month structure as the weight-loss plans, with no rung priced. Re-read 2026-08-26.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
1
Molecules with human evidence
For the use they are sold for, out of 2 products reviewed here. The evidence belongs to the molecule, not to LumiMeds.
1
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from LumiMeds’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Compounded GLP-1 injectionSemaglutide · Compounded (503A)Claim matches the trials
“All treatments are reviewed and prescribed by licensed providers through state-licensed compounding pharmacies. Payment does not guarantee a prescription. Compounded medications are not FDA-approved. Results may vary.”
Read on the LumiMeds site, August 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Semaglutide 2.4 mg over 68 weeks — the evidence for the FDA-approved product, which LumiMeds no longer claims applies to its compounded preparation.
The claim live on 2026-08-14 is not an efficacy claim at all — it is a disclaimer, and an accurate one. It states that treatments come through state-licensed compounding pharmacies (the correct licensing authority), that payment does not guarantee a prescription, and that compounded medications are not FDA-approved. This is a change, and the change is the point. FDA's 2025 letter cited the opposite: copy assigning FDA approval dates to the GLP-1 class and telling readers that “Doctors frequently recommend Compounded Tirzepatide or Compounded Semaglutide, both of which are GLP-1 agonists with the same active ingredient as the brand name medications.” None of that remains. The letter is still open, but the sentences it was about are not on the site.1
NAD+ injectableNAD+ · Compounded (503A)Claim matches the trials
“Start NAD+ injectables for as low as $119/mo.”
Read on the LumiMeds site, August 2026
No trial for this use
As of 2026-08-14 a read of its own site returned no trial, endpoint or outcome claim for NAD+ — only a price and a route. NAD+ is a real coenzyme; what is absent is trial evidence that injecting it produces the energy, focus or longevity outcomes this category markets it for, and LumiMeds asserts none of them.
There is no claim to grade. NAD+ appears as a product name, a route and a price, with no stated effect. Given that the trial evidence for injected NAD+ in the uses it is sold for does not exist, asserting nothing is the accurate position — and a notable one on a site that was previously written to about overclaiming.
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named. LumiMeds says treatments are prescribed “through state-licensed compounding pharmacies”, and its product pages now state the regulatory category outright — “SOURCE: 503A pharmacy · Compounded per your prescription · U.S. licensed”, which is more specific than the earlier wording and is the correct category. It still identifies no pharmacy: the footer's “Pharmacy Partnerships” link leads nowhere a reader can check, and the “Pricing” link in the same navigation leads to a page that does not exist. It does get the authority right — state-licensed, not FDA-licensed — which several companies in this batch do not.
Read on the LumiMeds site, August 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, potency result or purity result is published or offered, and no pharmacy is named who could be asked for one.
Read on the LumiMeds site, August 2026.
Licensing
Licensed to dispense, and where
Coverage
Re-checked 2026-08-26: no state list or exclusion set is published as such, but two things now point at nationwide coverage. Its medical director is described as “Licensed in all 50 states”, and the state question inside the assessment lists all fifty with none excluded. Neither is a coverage statement, so none is asserted here.
Read the full licensing claim
state-licensed compounding pharmacies, with a named medical director — Dr. Teresa Walsh, M.D., described as board certified in obesity medicine and licensed in all 50 states — overseeing clinical protocols
Read on the LumiMeds site, August 2026.
Regulatory
The FDA warning letter
Checked, and none found
We did this ourselves
What happens when you sign up with LumiMeds
We went through LumiMeds’s signup ourselves in August 2026 to find out what you actually meet before you pay — the steps, when a price appears, and what it asks for. We used placeholder answers, and we stopped before paying, so nothing here is a prescription or a medical outcome. It is what the screens showed.
- Press "See if you qualify". Three entry prices are already on the page.
- Say what brings you here, from four options.
- An overview screen: assessment 2 minutes, clinician review 5 hours, start today. Press "Check my eligibility".
- Say what would change if this worked, from five options.
- A basics screen: sex assigned at birth, first name, last name, state from a searchable list of all fifty, and date of birth.
- Height in feet and inches and weight, with a "Why BMI?" explainer beside it.
- This walk stopped at the height and weight screen, well before payment.
- Three entry prices sit on the home page before any question: compounded semaglutide from $89/mo, compounded tirzepatide from $125/mo, and NAD+ from $119/mo.
- Every one is an "as low as" floor. The product pages say "MONTHLY, 3, 6, AND 12 MONTH OPTIONS AVAILABLE" and price none of the four.
- The "Pricing" link in the site's own top navigation leads to a page that does not exist, so the one place a reader would look for the rungs does not exist.
- The plan cards say "No membership required" and the badge strip says "No Subscription Fees". The membership terms say "Membership plans are non-cancelable and non-refundable", that you may not terminate mid-term "for any reason, including but not limited to dissatisfaction, changes in personal health status, relocation", and that the rest of the term stays payable.
- The homepage tool that offers to show what your body can achieve returns 15% of whatever weight you enter — we tried 160, 195, 240 and 310 lb — while labeling the figure "Based on real LumiMeds patient outcomes" and "self-reported data from 6,342 LumiMeds patients on compounded tirzepatide".
- The compounded semaglutide page's dose ladder describes "dual-receptor activity" and says a provider "may continue increasing up to 15mg". Semaglutide is a single-receptor agonist and its approved ceiling is 2.4 mg a week; 15 mg is tirzepatide's. The tirzepatide page next door carries the correct version.
- Product pages state the source as a 503A pharmacy and repeat that compounded drugs are not FDA-approved as a finished product.
LumiMeds support
- Phone
- (415) 968-0890
- Hours
- Monday to Friday, 7 AM to 7 PM PST; Saturday and Sunday, 8 AM to 4 PM PST
Assessment
What holds up, and what does not
- The copy FDA cited is gone. The site now states “Compounded medications are not FDA-approved. Results may vary.” — the opposite of what the letter quoted.
- It names the correct licensing authority, state boards, rather than claiming FDA licensing or monitoring as several companies in this batch do.
- It says outright that payment does not guarantee a prescription, which is honest about a step most sites gloss over.
Show 5 more
- NAD+ is sold with no efficacy claim attached at all, which is the accurate position for a compound with no trial support for these uses.
- Entry prices for all three products are on public pages rather than behind an intake.
- Its product pages state the compounding category outright — 503A — and repeat that compounded drugs are not FDA-approved as a finished product.
- It names its medical director, Dr. Teresa Walsh, M.D., with a stated board certification in obesity medicine.
- Its testimonial block discloses that the members shown "were compensated for sharing their experience", which most of this market does not.
- The FDA warning letter (716510, September 2025) remains open, and a corrected website does not close a letter.
- No pharmacy is named, so the state-licensed claim cannot be checked against a licensee.
- No certificate of analysis or test result is published for any product.
Show 6 more
- Its membership terms read "Membership plans are non-cancelable and non-refundable" and bind you to "all outstanding payments for the remainder of the commitment term", on a site whose plan cards say "No membership required".
- Four plan lengths are offered — monthly, three, six and twelve months — and not one of them is priced. Every published figure is an "as low as" floor.
- The "Pricing" link in the site's own navigation leads to a page that does not exist.
- Its projection tool answers 15% of whatever weight you type, while presenting the number as drawn from 6,342 patients' reported outcomes.
- Its compounded semaglutide page describes "dual-receptor activity" and says a provider "may continue increasing up to 15mg" — a mechanism and a ceiling that belong to tirzepatide, not to semaglutide.
- NAD+ sits under a wellness framing that implies benefit the site never claims and no trial supports.
Verdict
The bottom line
Read the membership terms before the price. LumiMeds advertises three low floors and prices none of its four plan lengths, and its terms say a membership is non-cancelable and non-refundable once the term starts, with the balance still owed. Get the rung you are buying, its length and its total in writing first. On the claims side, judge this one on what it says now: the sentences FDA quoted are gone and the current disclaimer is accurate — the unnamed pharmacy, the absent test results and the open letter are not.
Opens www.lumimeds.com. A link is not a recommendation to take anything.
What FDA cited
In September 2025, FDA wrote to LumiMeds about two kinds of copy.
The first assigned approval dates to a drug class rather than a product:
"GLP-1 Injections contain GLP-1 … This is the same active ingredient used in brand name GLP-1 weight-loss medications. GLP-1 was FDA-approved in 2017 . . . . It was FDA-approved in 2021 for weight loss."
The second told readers the compounded products were equivalent:
"Doctors frequently recommend Compounded Tirzepatide or Compounded Semaglutide, both of which are GLP-1 agonists with the same active ingredient as the brand name medications."
FDA's position was that these imply the compounded products are the same as an FDA-approved product, which they are not.
Full analysis — 6 more sectionsWhat the site says now · What has not changed · The NAD+ listing · What it costs, and what you sign · Two numbers that came from a template · What this means if you are buying
What the site says now
"All treatments are reviewed and prescribed by licensed providers through state-licensed compounding pharmacies. Payment does not guarantee a prescription. Compounded medications are not FDA-approved. Results may vary."
None of the cited sentences remains. The current disclaimer states the opposite of what the letter quoted, names the correct licensing authority, and adds a caveat about prescriptions that nobody required it to add.
We have repeatedly recorded cases where a warning letter changed nothing — where the copy FDA quoted was still live months later. The symmetric case has to be reported the same way, or the record only ever runs in one direction.
What has not changed
The letter is still open. A corrected website does not close one, and nothing here should be read as saying it does.
No pharmacy is named. The product pages now state the category — "SOURCE: 503A pharmacy" — which is more than they used to say and is the correct category. No licensee is identified, and the footer's "Pharmacy Partnerships" link leads nowhere a reader can check. So the state-licensed claim is accurate in form and uncheckable in fact.
No test results. No certificate of analysis, no potency, no purity — and nobody named to ask.
The NAD+ listing
NAD+ appears as a name, a route and a price. No claim.
That is the correct handling. NAD+ is a genuine coenzyme, and the trial evidence for injecting it to produce energy, focus or longevity outcomes does not exist. A seller who says nothing cannot mislead; a seller who fills the silence usually does.
What it costs, and what you sign
Three floors are public before any question, which is more than most of this market offers:
- Compounded semaglutide — from $89/mo
- Compounded tirzepatide — from $125/mo
- NAD+ — from $119/mo
Every one of them is an "as low as". The product pages say "MONTHLY, 3, 6, AND 12 MONTH OPTIONS AVAILABLE" and then price none of the four, so the floor is presumably the twelve-month rung and the other three are unknown. The "Pricing" link in the site's own navigation leads to a page that does not exist, which is where a reader would go to settle it.
Then there are the membership terms, which are the most consequential thing on this site and are not linked from any product page. They say:
"Membership plans are non-cancelable and non-refundable. You may not terminate your Membership mid-term for any reason, including but not limited to dissatisfaction, changes in personal health status, relocation, or failure to engage with the services. All outstanding payments for the remainder of the commitment term shall remain due and payable."
The plan cards say "No membership required" and the badge strip says "No Subscription Fees". Both can be literally true — there is no separate membership fee — while the sentence above is also true of the plan you buy. Get the length and the total in writing before you pay.
The same terms reserve the right to change pricing "at its sole discretion" with 28 days' notice.
Two numbers that came from a template
The homepage carries a tool offering to show "what your body can achieve", labeled "Based on real LumiMeds patient outcomes" and footnoted to "self-reported data from 6,342 LumiMeds patients on compounded tirzepatide". Enter 160 lb and it answers 24. Enter 195 and it answers 29. Enter 240 and it answers 36; 310 and it answers "47+". Each of those is 15% of the number typed. The disclosure under it is unusually honest — n, method, "this is not a clinical trial", "compounded tirzepatide is not FDA-approved" — which makes the flat multiplier above it harder to explain, not easier.
The second is on the compounded semaglutide product page. Its dose ladder reads "a low starting point gives your body time to adjust to the dual-receptor activity" and, at month three, "your provider may continue increasing up to 15mg". Semaglutide acts on one receptor and its approved ceiling is 2.4 mg a week. Dual-receptor activity and a 15 mg ceiling belong to tirzepatide, whose page next door carries the correct wording. A reader on the semaglutide page is being shown another drug's mechanism and another drug's maximum dose.
What this means if you are buying
The evidence for the GLP-1 molecules is real and belongs to the approved products. 1 2 LumiMeds now says clearly that what it sells is not one of those, which is the sentence that matters.
Before ordering, ask which pharmacy compounds it, ask for the certificate of analysis for your lot, and ask what the plan you are being sold costs in total and how long it binds you. Those are the things this site still does not give you.
Questions
Frequently asked questions
Does LumiMeds still say its compounded GLP-1s are FDA-approved?
No. The copy FDA cited in 2025 — assigning approval dates to the GLP-1 class and describing compounded products as having the same active ingredient as brand-name medications — is no longer on the site. Its current disclaimer states that compounded medications are not FDA-approved.
Is the FDA warning letter closed?
No. Letter 716510, issued 9 September 2025, remains open. Correcting the website does not close a warning letter, and nothing here should be read as suggesting it has been.
Does LumiMeds claim anything for NAD+?
No. It appears as a product name, a route and a price, with no stated effect. Since trial evidence for injected NAD+ in the uses this category markets does not exist, asserting nothing is the accurate position.
Compare
Others selling what LumiMeds sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off LumiMeds's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 2 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.